ADC biotech Ona Therapeutics raises $86.6M in Series B to move two ADC candidates toward clinic
read at Endpoints ↗DealPositive
Barcelona-based Ona Therapeutics announced a $86.6 million Series B financing round.
The capital will be used to move two antibody‑drug conjugate (ADC) programs into early‑stage clinical testing.
CEO Valerie Vanhooren told Endpoints News that the money should fund the company for roughly two and a half years, supporting development and operational costs.
The raise underscores investor confidence in ADC technology and positions Ona Therapeutics to advance its pipeline.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “ADC biotech Ona Therapeutics secures $86.6M in Series B raise”
read at Endpoints ↗88 words · retrieved Jun 4
comments(0)
5-min edit window · permanent after that